Charles River Laboratories (CRL) stock soared 5.24% in Monday's intraday trading session. The rise appears to be driven by positive research updates from analysts covering the company.
According to TD Cowen, the firm cut its price target on CRL to $179 from $182 but maintained a Hold rating on the stock. The adjustment followed Charles River's recent financial results and likely factors in the analysts' updated outlook for the company.
Additionally, broader market sentiment towards Charles River Laboratories seems favorable, as evidenced by the news roundup highlighting various analysts raising their ratings and price targets on the stock. The positive analyst views suggest optimism around CRL's growth prospects and potential earnings performance.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。